Answers are grounded in this paper and cite their sources.
Case-control study reveals that VEGFA and HIF1A polymorphisms correlate with protein expression and survival in cholangiocarcinoma, highlighting their potential as prognostic biomarkers.
Background and aims Cholangiocarcinoma (CCA) represents 15% of liver tumors worldwide. Angiogenesis, a crucial process in tumor growth, involves participation of vascular endothelial growth factor A (VEGF-A) and hypoxia-inducible factor 1-alpha (HIF-1α). We analyzed polymorphisms, gene and protein expression of VEGFA and HIF1A and its association with survival in patients with CCA. Patients and methods A total of 65 patients with CCA and 30 individuals without liver diseases were studied. Genomic DNA and total RNA were extracted for allelic discrimination and gene expression, respectively, by reverse transcription qPCR and protein expression by immunohistochemistry. Results Patients with HIF1A -rs11549465 polymorphism (CT genotype) showed higher expression of HIF-1α versus the wild genotype (CC; p = 0.043); while VEGFA -rs3025039 (TT) and VEGF A-rs1570360 (GG) polymorphisms were associated with shorter ( p < 0.001) and longer survival ( p = 0.011), respectively. Conclusion Increased expression of HIF-1α in patients with HIF1A -rs11549465 polymorphism, and VEGFA polymorphisms (rs3025039 and rs1570360) associated with shorter and longer survival, respectively, highlighting the potential of these markers for prognostic prediction.
No takes yet. Share an insight, caveat, or question.
Fernandes-Ferreira et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: